Crisiane Wais Zanrosso
University of Caxias do Sul
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Crisiane Wais Zanrosso.
Cancer Epidemiology, Biomarkers & Prevention | 2010
Crisiane Wais Zanrosso; Mariana Emerenciano; Bruno Alves de Aguiar Gonçalves; Alessandra Faro; Sergio Koifman; Maria S. Pombo-de-Oliveira
Background: Maternal exposure to dipyrone during pregnancy has been associated with risk of infant leukemia (IL). N-Acetyltransferase 2 (NAT2) enzyme acetylates dipyrone, resulting in a detoxified metabolite. We performed genotyping to identify the distribution of NAT2 polymorphisms in duo samples from mothers and children previously investigated in a case-controlled study of IL. Methods: Samples from 132 IL, 131 age-matched controls, mothers of cases (n = 86), and mothers of controls (n = 36) were analyzed. PCR-RFLP assays were used to determine the NAT2 variants 191G>A, 282C>T, 341T>C, 481C>T, 590G>A, 803A>G, and 857G>A. The test for case-control differences in the distribution of genotypes was based on χ2 statistics. Unconditional logistic regression was used to examine the association between maternal exposure to dipyrone during the index pregnancy, IL, and NAT2 phenotypes. Crude and adjusted odds ratios (OR) are given with the 95% confidence interval (95% CI). Results: NAT2 slow-acetylation haplotypes were associated with IL (OR, 8.90; 95% CI, 1.71-86.7). An association between IL and NAT2 phenotype was observed in IL whether the mothers reported dipyrone exposures (OR, 4.48; 95% CI, 1.88-10.7) or not (OR, 4.27; 95% CI, 1.75-10.5). The combination of NAT2 slow/slow (mother/child) phenotypes confers a higher risk of IL (OR, 30.0; 95% CI, 5.87-279.7). Conclusion: NAT2 slow-acetylation profiles are associated with IL regardless of maternal exposure to dipyrone during pregnancy. Impact: Further recommendations about medicine exposures during pregnancy should take into account that infants with the maternal NAT2 slow-acetylation genotypes might be particularly vulnerable to greater risk. Cancer Epidemiol Biomarkers Prev; 19(12); 3037–43. ©2010 AACR.
Leukemia & Lymphoma | 2006
Flavio Ramos; Maria Tereza Cartaxo Muniz; Vanessa Cavalcante Silva; Marcela de Araújo; Ednalva Pereira Leite; Elizabete Malaquias Freitas; Crisiane Wais Zanrosso; Ana Hatagima; Maricilda Palandi de Mello; José Andrés Yunes; Terezinha de Jesus Marques-Salles; Neide Santos; Silvia Regina Brandalise; Maria S. Pombo-de-Oliveira
Methylenetetrahydrofolate reductase (MTHFR) is an essential enzyme in the metabolism of folate. The presence of polymorphisms that reduce the activity of MTHFR has been linked to the multifactor process of development of acute leukemia. A case control study was conducted on Brazilian children in different regions of the country with the aim of investigating the role of MTHFR C677T and A1298C polymorphisms as risk factors in the development of acute myeloid leukemia (AML). We used the polymerase chain reaction restriction fragment length polymorphism method to genotyping 182 AML and 315 healthy individuals. The genotype 677 CT was associated with decreased risk [odds ratio (OR), 0.37; confidence interval (CI) 95%, 0.14 – 0.92], whereas 1298 AC genotype was linked with an increased risk [OR, 2.90; CI 95%, 1.26 – 6.71] of developing AML in non-white children. Further epidemiological study is needed to unravel the complex multiple gene-environment interactions in the role of the AML leukemogenesis.
Leukemia & Lymphoma | 2012
Crisiane Wais Zanrosso; Mariana Emerenciano; Alessandra Faro; Bruno Alves de Aguiar Gonçalves; Marcela Braga Mansur; Maria S. Pombo-de-Oliveira
Abstract Seven single nucleotide polymorphisms (SNPs) were genotyped in 535 Brazilian children (158 with acute lymphoblastic leukemia [ALL], 74 with acute myeloid leukemia [AML] and 303 controls). The subjects were classified as fast or slow acetylators based on their genotypic variants. Logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals. N-acetyltransferase 2 (NAT2) SNP 341T > C frequency was higher among both leukemia subtypes compared to controls. There was also a significant difference in the frequency of SNP 590G > A in AML (OR, 1.57, 1.07–2.30). The haplotypes *14A, *5A and *5C conferred an increased risk in cases of ALL, while *14E, *6B and *6F conferred an increased risk for AML. An age-dependent analysis demonstrated that the NAT2 slow-acetylators conferred an increased risk association with leukemia in children ≤ 1 year old (OR, 7.91, 3.87–16.16) and also in older children (1 ≥ 10 years old) (OR, 1.53, 1.01–2.31). However, in this latter group the magnitude was reduced. The results demonstrate that the different NAT2 haplotypes contribute to the risk of either ALL or AML.
Pediatric Hematology and Oncology | 2008
Márcia R. Amorim; Crisiane Wais Zanrosso; Isis Quezado Magalhães; Simone C. Pereira; Alexandre Figueiredo; Mariana Emerenciano; Vitória Régia Pereira Pinheiro; Maria Lydia d'Andréa; Iêda M. Orioli; Sergio Koifman; Maria S. Pombo-de-Oliveira
Down syndrome (DS) is an important risk factor associated with acute leukemia (AL). The presence of polymorphisms that reduce 5,10-methylenetetrahydrofolate reductase (MTHFR) activity has been linked to the multifactorial leukemogenic process. The authors have conducted a study to test whether 677C→T and/or 1298A→C polymorphisms of MTHFR would play an additional role in susceptibility of acute myeloid leukemia (AML) in DS children. They also verified whether any polymorphism in the MTHFR gene was associated with the risk of DS. Genetic polymorphisms determination was carried out in 248 samples from healthy individuals as controls and a total of 115 DS children (65 without leukemia and 50 with AML). The present study failed to reveal any association between these polymorphisms and risk of AML in DS children. The data also indicate that MTHFR polymorphisms are not associated with risk of being a DS child.
Leukemia Research | 2006
Crisiane Wais Zanrosso; Ana Hatagima; Mariana Emerenciano; Flávio Ramos; Alexandre Figueiredo; Temis Maria Felix; Sandra Leistner Segal; Roberto Giugliani; Maria Tereza Cartaxo Muniz; Maria S. Pombo-de-Oliveira
Leukemia Research | 2009
Crisiane Wais Zanrosso; Ana Hatagima; Mariana Emerenciano; Flávio Ramos; Alexandre Figueiredo; Temis Maria Felix; Sandra Leistner Segal; Roberto Giugliani; Maria Tereza Cartaxo Muniz; Maria S. Pombo-de-Oliveira
Rev. bras. cancerol | 2005
Crisiane Wais Zanrosso; Mariana Emerenciano; Alexandre Figueiredo; Marcelo Reis; Synara Nô Seara Cordeiro; Alessandra Splendore; Maria S. Pombo-de-Oliveira
Rev. bras. cancerol | 2004
Mariana Emerenciano; Yomaira Bossa; Crisiane Wais Zanrosso; Dora Maria Alencar; Mércia Mendes Campos; Jane Dobbin; Kadma Carriço; Maria do Socorro Pombo de Oliveira
Archive | 2005
Crisiane Wais Zanrosso; Mariana Emerenciano; Alexandre Figueiredo; Marcelo Reis; Synara Nô; Seara Cordeiro; Alessandra Splendore; Maria S. Pombo-de-Oliveira
Archive | 2004
Mariana Emerenciano; Yomaira Bossa; Crisiane Wais Zanrosso; Dora Maria Alencar; Mércia Mendes Campos; Jane Dobbin; Kadma Carriço; Maria do Socorro Pombo de Oliveira